Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation
EAS 2019 - Maastricht, The Netherlands
EAS 2019 Paul Ridker discusses the positive effect of canakinumab on, in particular, non-small cell lung cancer incidence and mortality, as demonstrated in the CANTOS trial.
This video was recorded at the EAS in Maastricht, the Netherlands, on May 28, 2019.
Formally trained in cardiovascular medicine and epidemiology, Dr. Paul M Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women’s Hospital in Boston.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Share this page with your colleagues and friends: